Sponsors (16)
The bill strengthens federal oversight, inspections, reporting, and funding to improve the safety and traceability of compounded drugs, but it does so by imposing caps, reporting requirements, inspections, and fee authority that may raise costs, increase administrative burdens, and reduce patient access to customized compounded medications.
Patients who use compounded medications (and hospitals that administer them) will face lower risk of contaminated, improperly compounded, or inappropriately substituted products because the bill tightens limits on duplicative compounding, expands inspection requirements, improves data collection, and allows fees to fund oversight.
Pharmacies, physicians, and outsourcing facilities gain clearer regulatory boundaries and improved traceability through a clarified definition of 'commercially available' drugs, required reporting of out‑of‑state compounding volumes, and inclusion of certain facilities in device registration.
Manufacturers of approved, commercially available drugs (including small branded manufacturers) are better protected from substitution by compounders, helping preserve market share and brand integrity.
Patients who need customized compounded medications (e.g., due to shortages, allergies, or intolerance to commercial formulations) may have reduced access to those therapies because stricter limits on duplicative compounding, event thresholds, and narrower 'individualized' exceptions could prevent local or smaller compounders from providing needed alternatives.
Compounding pharmacies and outsourcing facilities face higher compliance costs from more frequent inspections, expanded registration, reporting obligations, and potentially higher fees—costs that may be passed to patients or result in reduced local supply or business closures.
Pharmacists, prescribers, and facility staff will incur added administrative and documentation burdens (monthly counts, annual reports, justification for individualized compounding, device registration), increasing workload and compliance overhead.
Based on analysis of 5 sections of legislative text.
Limits frequent compounding of copies of marketed drugs, requires annual reports and inspections for higher-volume compounding, and lets HHS set the base fee to fund oversight.
Introduced December 9, 2025 by Rudy Yakym · Last progress December 9, 2025
Limits how often pharmacies and physicians can compound products that are essentially copies of drugs available on the market, adds annual reporting when such compounded products are sent out of state, strengthens inspection and registration rules for high-volume outsourcing facilities, and gives HHS authority to set the base fee to support oversight. The bill defines when a compounded product counts as a copy of a commercially available drug, caps routine compounding of those copies at 20 times per month, requires annual reporting for out-of-state dispensing beginning in 2025, requires risk-based inspections for outsourcing facilities that compound a product more than 100 times per year, and replaces a fixed $5,000 base establishment fee with a Secretary-determined fee to fund oversight activities.